H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs HANCOCK PHARMACY II LLC

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
HANCOCK PHARMACY II LLC
CTRank #FEIN 27-2070565

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPHANCOCK PHARMACY II LLC
Total filings80,81363
Certified %98.23%88.89%
Denied %1.09%1.59%
Withdrawn %0.61%0.00%
Cert-withdrawn %0.07%9.52%
Rank#4
Active yearsFY2010–FY2026FY2010–FY2026
Worksite statePACT

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — HANCOCK PHARMACY II LLC

DOL case-status mix.

Outcome breakdown: Certified 88.9%, Cert-withdrawn 9.5%, Denied 1.6%
Outcome breakdown
OutcomeShare
Certified88.9%
Cert-withdrawn9.5%
Denied1.6%
Certified88.9%
Cert-withdrawn9.5%
Denied1.6%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
HANCOCK PHARMACY II LLC
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201014
FY20112
FY20124
FY201310
FY20149
FY20155
FY20165
FY20175
FY20183
FY20193
FY20200
FY20210
FY20220
FY20230
FY20240
FY20251
FY20262

Top 5 occupations — Deloitte Consulting LLP

Top 5 occupations — HANCOCK PHARMACY II LLC

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.